# EDGAR Filing Document

**Accession Number:** 0000026058
**File Stem:** 0000950170-25-098225
**Filing Date:** 2025-7
**Character Count:** 126798
**Document Hash:** 92059f40e041644e18287d6631bdddd7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-098225.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0000950170-25-098225

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 102

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CTS CORP
- **CENTRAL INDEX KEY:** 0000026058
- **STANDARD INDUSTRIAL CLASSIFICATION:** PRINTED CIRCUIT BOARDS [3672]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 350225010
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04639
- **FILM NUMBER:** 251145561

**BUSINESS ADDRESS:**
- **STREET 1:** 4925 INDIANA AVENUE
- **CITY:** LISLE
- **STATE:** IL
- **ZIP:** 60532
- **BUSINESS PHONE:** 6305778800

**MAIL ADDRESS:**
- **STREET 1:** 4925 INDIANA AVENUE
- **CITY:** LISLE
- **STATE:** IL
- **ZIP:** 60532

?xml version='1.0' encoding='ASCII'? 10-Q

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM** 10-Q

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For The Quarterly Period Ended** **<u>June 30,</u>** 2025

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Transition Period from to** 

**Commission File Number:** 1-4639

------

CTS CORPORATION

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| IN | 35-0225010 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(IRS Employer**<br>**Identification Number)** |

---

---

| | |
|:---|:---|
| 4925 Indiana Avenue |  |
| Lisle IL | 60532 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (**630**)** 577-8800

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| Common stock, without par value | CTS | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of July 17, 2025: 29,476,637.

------

CTS CORPORATION AND SUBSIDIARIES

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [<u>PART I. FINANCIAL INFORMATION</u>](#part_i_financial_information) | [<u>PART I. FINANCIAL INFORMATION</u>](#part_i_financial_information) |  |
| Item 1. | [<u>Financial Statements</u>](#item_1__financial_statements) | 3 |
|  | [<u>Condensed Consolidated Statements of Earnings (Unaudited) For the Three and Six Months Ended June 30, 2025 and June 30, 2024</u>](#condensed_consolidated_statements_earnin) | 3 |
|  | [<u>Condensed Consolidated Statements of Comprehensive Earnings (Unaudited) For the Three and Six Months Ended June 30, 2025 and June 30, 2024</u>](#condensed_consolidated_statements_compre) | 4 |
|  | [<u>Condensed Consolidated Balance Sheets As of June 30, 2025 (Unaudited) and December 31, 2024</u>](#condensed_consolidated_balance_sheets) | 5 |
|  | [<u>Condensed Consolidated Statements of Cash Flows (Unaudited) For the Six Months Ended June 30, 2025 and June 30, 2024</u>](#condensed_consolidated_statements_cash_f) | 6 |
|  | [<u>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) For the Three and Six Months Ended June 30, 2025 and June 30, 2024</u>](#condensed_consolidated_statements_shareh) | 7 |
|  | [<u>Notes to Condensed Consolidated Financial Statements - (Unaudited)</u>](#notes_to_condensed_consolidated_financia) | 9 |
| Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item_2_managements_discussion_analysis_f) | 29 |
| Item 3. | [<u>Quantitative and Qualitative Disclosures about Market Risk</u>](#item_3__quantitative_qualitative_disclos) | 35 |
| Item 4. | [<u>Controls and Procedures</u>](#item_4__controls_procedures) | 36 |
| [<u>PART II. OTHER INFORMATION</u>](#part_ii_or_information) | [<u>PART II. OTHER INFORMATION</u>](#part_ii_or_information) |  |
| Item 1. | [<u>Legal Proceedings</u>](#item_1_legal_proceedings) | 36 |
| Item 1A. | [<u>Risk Factors</u>](#item_1a_risk_factors) | 36 |
| Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 37 |
| Item 5. | [<u>Other Information</u>](#item_5_other_information) | 37 |
| Item 6. | [<u>Exhibits</u>](#item_6_exhibits) | 38 |
| [<u>SIGNATURES</u>](#signatures) | [<u>SIGNATURES</u>](#signatures) | 39 |

---

------

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**CTS CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS - UNAUDITED**

*(In thousands, except per share amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | $135309 | $130162 | $261078 | $255912 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 82878 | 83790 | 162099 | 164450 |
| Gross margin | 52431 | 46372 | 98979 | 91462 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 23077 | 21332 | 46700 | 43591 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | 6326 | 6086 | 12515 | 12687 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 297 | 1190 | 749 | 2884 |
| Operating earnings | 22731 | 17764 | 39015 | 32300 |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (1121) | (833) | (2289) | (1635) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 622 | 1441 | 1068 | 2827 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | 750 | (603) | 1307 | (2066) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense), net | 251 | 5 | 86 | (874) |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before income taxes | 22982 | 17769 | 39101 | 31426 |
| Income tax expense | 4455 | 3062 | 7210 | 5600 |
| **Net earnings** | $18527 | $14707 | $31891 | $25826 |
| **Earnings per share:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.62 | $0.48 | $1.07 | $0.84 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.62 | $0.48 | $1.06 | $0.84 |
| **Basic weighted – average common shares outstanding:** | 29739 | 30511 | 29875 | 30627 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive securities | 251 | 219 | 285 | 224 |
| **Diluted weighted – average common shares outstanding:** | 29990 | 30730 | 30160 | 30851 |
| **Cash dividends declared per share** | $0.04 | $0.04 | $0.08 | $0.08 |

---

See notes to unaudited condensed consolidated financial statements.

------

**CTS CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS** - **UNAUDITED**

*(In thousands)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Net earnings** | $18527 | $14707 | $31891 | $25826 |
| Other comprehensive earnings (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in fair market value of derivatives, net of tax | 2847 | (1675) | 3723 | (944) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in unrealized pension cost, net of tax | (123) | 35 | (109) | 99 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustment, net of tax | 8024 | (523) | 12672 | (2644) |
| Other comprehensive earnings (loss) | $10748 | $(2163) | $16286 | $(3489) |
| **Comprehensive earnings** | $29275 | $12544 | $48177 | $22337 |

---

See notes to unaudited condensed consolidated financial statements.

------

**CTS CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

*(In thousands)*

---

| | | |
|:---|:---|:---|
|  | **(Unaudited)** |  |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| **ASSETS** |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $99440 | $94334 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 85578 | 77649 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 57103 | 52312 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 19629 | 17879 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 261750 | 242174 |
| Property, plant and equipment, net | 93530 | 94357 |
| Operating lease assets, net | 21709 | 22939 |
| Other Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 207547 | 201304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets, net | 161785 | 163882 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 26714 | 27591 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 11694 | 13180 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other assets | 407740 | 405957 |
| **Total Assets** | $784729 | $765427 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $47265 | $42629 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease obligations | 4557 | 4719 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and benefits | 17444 | 15754 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 31200 | 35361 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 100466 | 98463 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 88000 | 92300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term operating lease obligations | 19999 | 21120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term pension obligations | 3872 | 3931 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 14233 | 12743 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term obligations | 8002 | 8662 |
| **Total Liabilities** | 234572 | 237219 |
| Commitments and Contingencies (Note 9) |  |  |
| Shareholders' Equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 324682 | 321979 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional contributed capital | 41236 | 44662 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 682360 | 652851 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 12020 | (4266) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity before treasury stock | 1060298 | 1015226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock | (510141) | (487018) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 550157 | 528208 |
| **Total Liabilities and Shareholders' Equity** | $784729 | $765427 |

---

See notes to unaudited condensed consolidated financial statements.

------

**CTS CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** - **UNAUDITED**

*(In thousands)*

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net earnings | $31891 | $25826 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net earnings to net cash provided by operating<br> activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 17045 | 14651 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and other post-retirement plan expense | 117 | 171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 2263 | 2544 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (84) | (1236) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration liability | (1523) | (572) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on foreign currency hedges, net of cash | 65 | (278) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (5181) | (7884) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (2960) | 7665 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease assets | 1230 | 2244 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 1404 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 3017 | (2048) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and benefits | 354 | 899 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (1282) | (2248) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (2402) | (1736) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and other post-retirement plans | (84) | (83) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | 43870 | 37940 |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (7745) | (8672) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | (7745) | (8672) |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments of long-term debt | (541700) | (335000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from borrowings of long-term debt | 537400 | 332500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of treasury stock | (22995) | (22892) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid | (2401) | (2460) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of contingent consideration |  | (1076) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes paid on behalf of equity award participants | (2655) | (3131) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | (32351) | (32059) |
| Effect of exchange rate changes on cash and cash equivalents | 1332 | 161 |
| **Net increase (decrease) in cash and cash equivalents** | 5106 | (2630) |
| Cash and cash equivalents at beginning of period | 94334 | 163876 |
| **Cash and cash equivalents at end of period** | $99440 | $161246 |
| **Supplemental cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $2169 | $1554 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes, net | $7092 | $8064 |
| **Non-cash financing and investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures incurred but not paid | $1700 | $1943 |
| &nbsp;&nbsp;&nbsp;&nbsp;Excise taxes on purchase of treasury stock incurred not paid | $127 | $460 |

---

See notes to unaudited condensed consolidated financial statements.

------

**CTS CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - UNAUDITED**

*(in thousands, except shares and per share amounts)*

The following summarizes the changes in total equity for the three and six months ended June 30, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common<br>Stock** | **Additional<br>Contributed <br>Capital** | **Retained<br>Earnings** | **Accumulated<br>Other <br>Comprehensive Income<br>(Loss)** | **Treasury<br>Stock** | **Total** |
| **Balances at December 31, 2024** | $321979 | $44662 | $652851 | $(4266) | $(487018) | $528208 |
| Net earnings |  |  | 13367 |  |  | 13367 |
| Changes in fair market value of derivatives, net of tax |  |  |  | 876 |  | 876 |
| Changes in unrealized pension cost, net of tax |  |  |  | 14 |  | 14 |
| Cumulative translation adjustment, net of tax |  |  |  | 4648 |  | 4648 |
| Cash dividends of $0.04 per share |  |  | (1201) |  |  | (1201) |
| Acquired 143,541 shares of treasury stock |  |  |  |  | (6472) | (6472) |
| Issued shares on vesting of restricted stock units | 2656 | (5290) |  |  |  | (2634) |
| Stock compensation |  | 1432 |  |  |  | 1432 |
| **Balances at March 31, 2025** | $324635 | $40804 | $665017 | $1272 | $(493490) | $538238 |
| Net earnings |  |  | 18527 |  |  | 18527 |
| Changes in fair market value of derivatives, net of tax |  |  |  | 2847 |  | 2847 |
| Changes in unrealized pension cost, net of tax |  |  |  | (123) |  | (123) |
| Cumulative translation adjustment, net of tax |  |  |  | 8024 |  | 8024 |
| Cash dividends of $0.04 per share |  |  | (1184) |  |  | (1184) |
| Acquired 411,650 shares of treasury stock |  |  |  |  | (16651) | (16651) |
| Issued shares on vesting of restricted stock units | 47 | (68) |  |  |  | (21) |
| Stock compensation |  | 500 |  |  |  | 500 |
| **Balances at June 30, 2025** | $324682 | $41236 | $682360 | $12020 | $(510141) | $550157 |

---

See notes to unaudited condensed consolidated financial statements.

------

**CTS CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - UNAUDITED**

*(in thousands, except shares and per share amounts)*

The following summarizes the changes in total equity for the three and six months ended June 30, 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common<br>Stock** | **Additional<br>Contributed <br>Capital** | **Retained<br>Earnings** | **Accumulated<br>Other <br>Comprehensive Income<br>(Loss)** | **Treasury<br>Stock** | **Total** |
| **Balances at December 31, 2023** | $319269 | $45097 | $602232 | $4264 | $(444040) | $526822 |
| Net earnings |  |  | 11119 |  |  | 11119 |
| Changes in fair market value of derivatives, net of tax |  |  |  | 730 |  | 730 |
| Changes in unrealized pension cost, net of tax |  |  |  | 65 |  | 65 |
| Cumulative translation adjustment, net of tax |  |  |  | (2121) |  | (2121) |
| Cash dividends of $0.04 per share |  |  | (1227) |  |  | (1227) |
| Acquired 271,939 shares of treasury stock |  |  |  |  | (12035) | (12035) |
| Issued shares on vesting of restricted stock units | 2589 | (5705) |  |  |  | (3116) |
| Stock compensation |  | 1048 |  |  |  | 1048 |
| **Balances at March 31, 2024** | $321858 | $40440 | $612124 | $2938 | $(456075) | $521285 |
| Net earnings |  |  | 14707 |  |  | 14707 |
| Changes in fair market value of derivatives, net of tax |  |  |  | (1675) |  | (1675) |
| Changes in unrealized pension cost, net of tax |  |  |  | 35 |  | 35 |
| Cumulative translation adjustment, net of tax |  |  |  | (523) |  | (523) |
| Cash dividends of $0.04 per share |  |  | (1217) |  |  | (1217) |
| Acquired 228,000 shares of treasury stock |  |  |  |  | (11043) | (11043) |
| Issued shares on vesting of restricted stock units | 36 | (49) |  |  |  | (13) |
| Stock compensation |  | 1195 |  |  |  | 1195 |
| **Balances at June 30, 2024** | $321894 | $41586 | $625614 | $775 | $(467118) | $522751 |

---

See notes to unaudited condensed consolidated financial statements.

------

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED**

(in thousands, except for share and per share data)

June 30, 2025

**NOTE 1 - Basis of Presentation**

The accompanying condensed consolidated financial statements have been prepared by CTS Corporation ("CTS", "we", "our", "us" or the "Company"), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements should be read in conjunction with the financial statements, notes thereto, and other information included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

The accompanying unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring items) necessary for a fair statement, in all material respects, of the financial position and results of operations for the periods presented. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ materially from those estimates. The results of operations for the interim periods are not necessarily indicative of the results for the entire year.

There have been no material changes in the Company's significant accounting policies as compared to the significant accounting policies described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

**Immaterial Correction of Prior Period Error**

As reported in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, the Company identified immaterial prior period errors in the consolidated financial statements related to the acquisition of SyQwest, LLC ("SyQwest") as well as the foreign currency impact on certain long-term debt payments. The errors related to the SyQwest acquisition were due to errors with the calculation of revenue and cost of goods sold both prior to and subsequent to the acquisition date of July 29, 2024. The Company assessed the materiality of this change on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, "Materiality" (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these error corrections were material in the first quarter of 2025, but are not material to any previously presented consolidated financial statements. Accordingly, the Company corrected the previously reported immaterial errors for the year ended December 31, 2024 and the three and nine months ended September 30, 2024 in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025.

The financial reporting periods affected by this error include the Company's previously reported audited consolidated financial statements for the fiscal year ended December 31, 2024 and the Company's previously reported interim unaudited consolidated financial statements for the three and nine months ended September 30, 2024. In addition, the Company expects to present the corrected interim 2024 amounts in its 2025 consolidated interim financial statements upon the filing of each of its Quarterly Reports on Form 10-Q on a year-to-date basis as a correction to applicable 2024 periods. A summary of the immaterial corrections to the Company's previously reported audited and unaudited consolidated financial statements follows.

------

**Corrected Consolidated Statement of Earnings for the Year Ended December 31, 2024 (in thousands):** 

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended** |  | **Year Ended** |
|  | **December 31, 2024** |  | **December 31, 2024** |
|  | **Previously Reported** | **Corrections** | **As Corrected** |
| **Net sales** | $515771 | $(1015) | $514756 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 326621 | 580 | 327201 |
| Gross margin | 189150 | (1595) | 187555 |
| Operating earnings | 72780 | (1595) | 71185 |
| Other income (expense): |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | (1603) | (1047) | (2650) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense, net | (1557) | (1047) | (2604) |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before income taxes | 71223 | (2642) | 68581 |
| **Net earnings** | $58114 | $(2642) | $55472 |
| **Earnings per share:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $1.91 |  | $1.82 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $1.89 |  | $1.81 |
| **Basic weighted – average common shares outstanding:** | 30408 |  | 30408 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive securities | 309 |  | 309 |
| **Diluted weighted – average common shares outstanding:** | 30717 |  | 30717 |

---

**Corrected Consolidated Balance Sheet as of December 31, 2024 (in thousands):**

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31, 2024** |  | **December 31, 2024** |
|  | **Previously Reported** | **Corrections** | **As Corrected** |
| **ASSETS** |  |  |  |
| Current Assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | $53578 | $(1266) | $52312 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 18716 | (837) | 17879 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 244277 | (2103) | 242174 |
| Other Assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 199886 | 1418 | 201304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other assets | 404539 | 1418 | 405957 |
| **Total Assets** | $766112 | $(685) | $765427 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |  |
| Current Liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 34451 | 910 | 35361 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 97553 | 910 | 98463 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 91253 | 1047 | 92300 |
| **Total Liabilities** | 235262 | 1957 | 237219 |
| Shareholders' Equity |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 655493 | (2642) | 652851 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity before treasury stock | 1017868 | (2642) | 1015226 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 530850 | (2642) | 528208 |
| **Total Liabilities and Shareholders' Equity** | $766112 | $(685) | $765427 |

---

------

**Corrected Consolidated Statement of Cash Flows for the Year Ended December 31, 2024 (in thousands):**

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended** |  | **Year Ended** |
|  | **December 31, 2024** |  | **December 31, 2024** |
|  | **Previously Reported** | **Corrections** | **As Corrected** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net earnings | $58114 | $(2642) | $55472 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 11893 | 580 | 12473 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 900 | 837 | 1737 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (5255) | 178 | (5077) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | 99289 | (1047) | 98242 |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments of long-term debt | (891847) | 1047 | (890800) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash (used in) provided by financing activities** | $(27935) | $1047 | $(26888) |

---

**Corrected Consolidated Statement of Earnings for the Three and Nine Months Ended September 30, 2024 (in thousands):** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** |  | **Three Months Ended** | **Nine Months Ended** |  | **Nine Months Ended** |
|  | **September 30, 2024** |  | **September 30, 2024** | **September 30, 2024** |  | **September 30, 2024** |
|  | **Previously Reported** | **Corrections** | **As Corrected** | **Previously Reported** | **Corrections** | **As Corrected** |
| **Net sales** | $132424 | $(40) | $132385 | $388336 | $(40) | $388296 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 82636 | 559 | 83195 | 247086 | 559 | 247645 |
| Gross margin | 49788 | (599) | 49189 | 141250 | (599) | 140651 |
| Operating earnings | 21475 | (599) | 20876 | 53775 | (599) | 53176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before income taxes | 22447 | (599) | 21848 | 53872 | (599) | 53273 |
| **Net earnings** | $18683 | $(599) | $18084 | $44508 | $(599) | $43909 |
| **Earnings per share:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.62 |  | $0.60 | $1.46 |  | $1.44 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.61 |  | $0.59 | $1.45 |  | $1.43 |
| **Basic weighted – average common shares outstanding:** | 30300 |  | 30300 | 30517 |  | 30517 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive securities | 236 |  | 236 | 230 |  | 230 |
| **Diluted weighted – average common shares outstanding:** | 30536 |  | 30536 | 30747 |  | 30747 |

---

------

**Corrected Consolidated Balance Sheet as of September 30, 2024 (in thousands):** 

---

| | | | |
|:---|:---|:---|:---|
|  | **September 30, 2024** |  | **September 30, 2024** |
|  | **Previously Reported** | **Corrections** | **As Corrected** |
| **ASSETS** |  |  |  |
| Current Assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | $57288 | $(1246) | $56042 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 255561 | (1246) | 254315 |
| Other Assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 194821 | 1418 | 196239 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other assets | 416677 | 1418 | 418095 |
| **Total Assets** | $789392 | $172 | $789564 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |  |
| Current Liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 37249 | 771 | 38020 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 103799 | 771 | 104570 |
| **Total Liabilities** | 258586 | 771 | 259357 |
| Shareholders' Equity |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 643088 | (599) | 642489 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity before treasury stock | 1009937 | (599) | 1009338 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 530806 | (599) | 530207 |
| **Total Liabilities and Shareholders' Equity** | $789392 | $172 | $789564 |

---

**Corrected Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2024 (in thousands):** 

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended** |  | **Nine Months Ended** |
|  | **September 30, 2024** |  | **September 30, 2024** |
|  | **Previously Reported** | **Corrections** | **As Corrected** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net earnings | $44508 | $(599) | $43909 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 11346 | 559 | 11905 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (2645) | 40 | (2605) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | $73335 | $- | $73335 |

---

**Corrected Fair Value of SyQwest Assets Acquired and Liabilities Assumed:**

---

| | |
|:---|:---|
|  | **Fair Values at<br>July 29, 2024** |
| Accounts receivable | $770 |
| Inventory | 7939 |
| Other current assets | 1475 |
| Property, plant and equipment | 985 |
| Other assets | 684 |
| Goodwill | 46600 |
| Intangible assets | 76100 |
| Fair value of assets acquired | 134553 |
| Less fair value of liabilities acquired | (6536) |
| Purchase price | $128017 |

---

------

**Accounting Pronouncements Recently Adopted**

**ASU No. 2023-07, "*Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure"***

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments' significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as existing segment disclosures and reconciliation required under ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for the interim periods beginning after December 15, 2024, with early adoption permitted. We adopted the guidance in our Annual Report on Form 10-K for the year ended December 31, 2024. See Note 17, "Segment Information," for further information.

**Recently issued accounting pronouncements not yet adopted**

**ASU No. 2023-09, "*Income Taxes (Topic 740): Improvements to Income Tax Disclosures"***

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the reconciliation of the effective tax rate, as well as disclosure of income taxes paid, disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09. We will adopt the guidance when it becomes effective on a prospective basis.

**ASU No. 2024-03, "*Income Statement (Subtopic 220-40): Disaggregation of Income Statement Expenses"***

In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional information about certain expenses in the notes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. We will adopt the guidance when it becomes effective on a prospective basis.

**NOTE 2 – Revenue Recognition**

CTS designs and manufactures sensors, actuators, and electronic components for original equipment manufacturers and the U.S. Government. For each contract with a customer, we determine the transaction price based on the consideration expected to be received by the Company in exchange for performing its obligations under the applicable contract. We allocate the transaction price to each distinct performance obligation to deliver a good or service, or a collection of goods and/or services, based on the relative standalone selling prices. We usually expect payment from our customers within 30 to 90 days from the shipping date or invoicing date, depending on our terms with the customer. None of our contracts as of June 30, 2025 contained a significant financing component. Differences between the amount of revenue recognized and the amount invoiced, collected from, or paid to our customers are recognized as contract assets or liabilities. Contract assets will be reviewed for impairment when events or circumstances indicate that they may not be recoverable.

To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the most likely value method based on an analysis of historical experience and current facts and circumstances, which may require significant judgment. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur.

The majority of our revenue is derived from contracts for sales of commercial products, which generally contain a single performance obligation. We generally recognize revenue at a point in time on the delivery date based on the shipping terms stipulated in the contract.

------

We also design, manufacture, and test products for certain customers under contracts that allow the customers to unilaterally terminate the contract for convenience, take control of any work in process, and pay us for costs incurred plus a reasonable profit. Revenue from these contracts is generally recognized over time as the work progresses, either as products are produced or services are rendered, because we generally do not have an alternative use for the completed assets produced and we have an enforceable right to payment for performance completed to date. These contracts may contain a single or multiple performance obligations. The accounting for these contracts involves applying significant judgment with respect to estimating total revenues, costs and profit for each performance obligation. We generally estimate revenue for these contracts using the costs incurred by the Company as we have determined it is most representative of the Company's cumulative efforts relative to the total expected efforts to satisfy the performance obligations.

See Note 9, "Commitments and Contingencies" for information about our product warranties.

**Contract Assets and Liabilities**

Contract assets and liabilities included in our Condensed Consolidated Balance Sheets are as follows:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| **Contract Assets** |  |  |
| &nbsp;&nbsp;Unbilled customer receivables included in Other current assets | $2590 | $4104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Contract Assets** | $2590 | $4104 |
| **Contract Liabilities** |  |  |
| &nbsp;&nbsp;Customer advance payments included in Accrued expenses and other liabilities | $(810) | $(910) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Contract Liabilities** | $(810) | $(910) |

---

During the six months ended June 30, 2025 the Company recognized $100 of revenue that was included in the contract liability balance at December 31, 2024.

**Disaggregated Revenue**

The following table presents revenues disaggregated by the major markets we serve:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Transportation | $60674 | $64221 | $119163 | $130738 |
| Industrial | 34110 | 32175 | 66558 | 63238 |
| Medical | 19177 | 17832 | 38308 | 34733 |
| Aerospace & Defense | 21348 | 15934 | 37049 | 27203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $135309 | $130162 | $261078 | $255912 |

---

**NOTE 3 – Accounts Receivable, net**

The components of accounts receivable, net are as follows:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Accounts receivable, gross | $86558 | $78379 |
| Less: Allowance for credit losses | (980) | (730) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | $85578 | $77649 |

---

------

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2024** | **2023** |
| Accounts receivable, gross | $86092 | $79500 |
| Less: Allowance for credit losses | (712) | (931) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | $85380 | $78569 |

---

**NOTE 4 – Inventories, net**

Inventories, net consists of the following:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Finished goods | $12504 | $12126 |
| Work-in-process | 27521 | 22331 |
| Raw materials | 30928 | 31818 |
| Less: Inventory reserves | (13850) | (13963) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | $57103 | $52312 |

---

**NOTE 5 – Property, Plant and Equipment, net**

Property, plant and equipment, net is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Land and land improvements | $399 | $399 |
| Buildings and improvements | 73423 | 73011 |
| Machinery and equipment | 272284 | 265950 |
| Less: Accumulated depreciation | (252576) | (245003) |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net | $93530 | $94357 |

---

Depreciation expense for the three months ended June 30, 2025 and June 30, 2024 was $4,508 and $4,518, respectively. Depreciation expense for the six months ended June 30, 2025 and June 30, 2024 was $8,970 and $9,018, respectively.

**NOTE 6 – Goodwill and Other Intangible Assets**

*Goodwill*

Changes in the net carrying amount of goodwill were as follows:

---

| | |
|:---|:---|
|  | **Total** |
| Goodwill as of December 31, 2024 | $201304 |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign exchange impact | 6243 |
| Goodwill as of June 30, 2025 | $207547 |

---

*Other Intangible Assets*

Other intangible assets, net consist of the following components:

---

| | | | |
|:---|:---|:---|:---|
|  | **As of** | **As of** | **As of** |
|  | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** |
|  | **Gross<br>Carrying <br>Amount** | **Accumulated<br>Amortization** | **Net Amount** |
| Customer lists/relationships | $217035 | $(80182) | $136853 |
| Technology and other intangibles | 62197 | (37265) | 24932 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets, net | $279232 | $(117447) | $161785 |

---

------

---

| | | | |
|:---|:---|:---|:---|
|  | **As of** | **As of** | **As of** |
|  | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Gross<br>Carrying <br>Amount** | **Accumulated<br>Amortization** | **Net Amount** |
| Customer lists/relationships | $210354 | $(72500) | $137854 |
| Technology and other intangibles | 61244 | (35216) | 26028 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets, net | $271598 | $(107716) | $163882 |

---

Amortization expense for the three months ended June 30, 2025 and June 30, 2024 was $4,044 and $2,807, respectively. Amortization expense for the six months ended June 30, 2025 and June 30, 2024 was $8,075 and $5,633, respectively.

Remaining amortization expense for other intangible assets as of June 30, 2025 is as follows:

---

| | |
|:---|:---|
|  | **Amortization<br>expense** |
| Remaining 2025 | $8100 |
| 2026 | 16155 |
| 2027 | 16094 |
| 2028 | 16059 |
| 2029 | 14892 |
| Thereafter | 90485 |
| Total amortization expense | $161785 |

---

**NOTE 7 – Costs Associated with Exit and Restructuring Activities**

Restructuring charges are reported as a separate line within operating earnings in the Condensed Consolidated Statements of Earnings.

Total restructuring charges are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| Restructuring charges | $297 | $1190 |

---

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| Restructuring charges | $749 | $2884 |

---

During the three months ended June 30, 2025, we incurred total restructuring charges of $297, comprised of $293 and $4 in workforce reduction and building and equipment relocation costs, respectively. During the six months ended June 30, 2025, we incurred total restructuring charges of $749, comprised of $687, $25 and $37 in workforce reduction, building and equipment relocation costs, and asset impairment and other charges, respectively. The workforce reduction charges incurred are for restructuring activities used to adjust our business in response to reduced demand across certain locations and products. Restructuring charges incurred in relation to building and equipment relocation costs and other charges are for activities intended to consolidate operations across our site locations. The remaining liability associated with our other restructuring actions was $734 and $798 at June 30, 2025 and December 31, 2024, respectively.

The following table displays the restructuring liability activity included in accrued expenses and other liabilities for the six months ended June 30, 2025:

---

| | |
|:---|:---|
| Restructuring liability at December 31, 2024 | $798 |
| Restructuring charges | 749 |
| Costs paid | (813) |
| Restructuring liability at June 30, 2025 | $734 |

---

------

**NOTE 8 – Accrued Expenses and Other Liabilities**

The components of accrued expenses and other liabilities are as follows:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Accrued product-related costs | $1939 | $1866 |
| Accrued income taxes | 5422 | 5418 |
| Accrued property and other taxes | 1327 | 1518 |
| Accrued professional fees | 1775 | 1625 |
| Accrued customer-related liabilities | 1581 | 2113 |
| Dividends payable | 1182 | 1201 |
| Remediation reserves | 11891 | 12192 |
| Derivative liabilities | 1092 | 334 |
| Other accrued liabilities | 4991 | 9094 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accrued expenses and other liabilities | $31200 | $35361 |

---

**NOTE 9 – Commitments and Contingencies**

Certain processes in the manufacture of our current and past products may create by-products classified as hazardous waste. As a result, we have been notified by the U.S. Environmental Protection Agency ("EPA"), state environmental agencies and in some cases, groups of potentially responsible parties, that we may be potentially liable for environmental contamination at several sites currently or formerly owned or operated by us. Currently, none of these costs and accruals relate to sites that provide revenue generating activities for the Company. Two of those sites, Asheville, North Carolina (the "Asheville Site") and Mountain View, California, are designated National Priorities List sites under the EPA's Superfund program. We accrue a liability for probable remediation activities, claims, and proceedings against us with respect to environmental matters if the amount can be reasonably estimated, and provide disclosures including the nature of a loss whenever it is probable or reasonably possible that a potentially material loss may have occurred but cannot be estimated. We record contingent loss accruals on an undiscounted basis.

A roll-forward of remediation reserves included in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Balance at beginning of period | $12192 | $12044 |
| Remediation expense | 438 | 1701 |
| Net remediation payments | (745) | (1554) |
| Other activity<sup>(1)</sup> | 6 | 1 |
| Balance at end of the period | $11891 | $12192 |

---

<sup>(1)</sup> Other activity includes currency translation adjustments not recorded to remediation expense.

The Company operates under and in accordance with a federal consent decree, dated March 7, 2017, with the EPA for the Asheville Site. On February 8, 2023, the Company received a pre-litigation letter from the EPA (the "EPA Letter") seeking reimbursement of its past response costs and interest thereon relating to any release or threatened release of hazardous substances at the Asheville Site in the aggregate amount of $9,955 from the three potentially responsible parties associated with the Asheville Site, including the Company. The matter remains in the pre-litigation phase. The Company expects its potential exposure to be between $1,900 and $9,955. We have determined that no point within this range is more likely than another and, therefore, we have recorded a loss estimate of $1,900 as of June 30, 2025 and December 31, 2024 in the Consolidated Balance Sheets.

------

Unrelated to the environmental claims described above, certain other legal claims are pending against us with respect to matters arising out of the ordinary conduct of our business.

We provide product warranties when we sell our products and accrue for estimated liabilities at the time of sale. Warranty estimates are forecasts based on the best available information and historical claims experience. We accrue for specific warranty claims if we believe that the facts of a specific claim make it probable that a liability in excess of our historical experience has been incurred, and provide disclosures for specific claims whenever it is reasonably possible that a material loss may be incurred which cannot be estimated.

We cannot provide assurance that the ultimate disposition of environmental, legal, and product warranty claims will not materially exceed the amount of our accrued losses and adversely impact our consolidated financial position, results of operations, or cash flows. Our accrued liabilities and disclosures will be adjusted accordingly if additional information becomes available in the future.

**NOTE 10 - Debt**

Long-term debt is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Total credit facility | $400000 | $400000 |
| Balance outstanding | 88000 | 92300 |
| Standby letters of credit | 1640 | 1640 |
| Amount available, subject to covenant restrictions | $310360 | $306060 |
| Weighted-average interest rate | 5.64% | 6.41% |

---

On December 15, 2021, we entered into a second amended and restated five-year credit agreement with a group of banks (the "Revolving Credit Facility") to (i) increase the total credit facility to $400,000, which may be increased by $200,000 at the request of the Company, subject to the administrative agent's approval, (ii) extend the maturity of the Revolving Credit Facility from February 12, 2024 to December 15, 2026, (iii) replace LIBOR with SOFR as the primary reference rate used to calculate interest on the loans under the Revolving Credit Facility, (iv) increase available sub limits for letters of credit and swing line loans as well as providing for additional alternative currency borrowing capabilities, and (v) modify the financial and non-financial covenants to provide the Company additional flexibility. This unsecured credit facility replaced the prior $300,000 unsecured credit facility, which would have expired February 12, 2024.

Borrowings in U.S. dollars under the Revolving Credit Facility bear interest, at a per annum rate equal to the applicable Term SOFR rate (but not less than 0.0%), plus the Term SOFR adjustment, and plus an applicable margin, which ranges from 1.00% to 1.75%, based on our net leverage ratio. Similarly, borrowings of alternative currencies under the Revolving Credit Facility bear interest equal to a defined risk-free reference rate, plus the applicable risk-free rate adjustment and plus an applicable margin, which ranges from 1.00% to 1.75%, based on our net leverage ratio. We use interest rate swaps to convert a portion of our revolving credit facility's outstanding balance from a variable rate of interest to a fixed rate. The contractual rate of these arrangements ranges from 1.49% to 2.45%. Refer to Note 11, "Derivative Financial Instruments," for further discussion on the impact of interest rate swaps.

The Revolving Credit Facility includes a swing line sublimit of $20,000 and a letter of credit sublimit of $20,000. We also pay a quarterly commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee ranges from 0.175% to 0.25% based on our net leverage ratio.

------

The Revolving Credit Facility requires, in addition to customary representations and warranties, that we comply with a maximum net leverage ratio and a minimum interest coverage ratio. Failure to comply with these covenants could reduce the borrowing availability under the Revolving Credit Facility. We were in compliance with all debt covenants at June 30, 2025. The Revolving Credit Facility requires that we deliver quarterly financial statements, annual financial statements, auditor certifications, and compliance certificates within a specified number of days after the end of a quarter and year. Additionally, the Revolving Credit Facility contains restrictions limiting our ability to: dispose of assets; incur certain additional debt; repay other debt or amend subordinated debt instruments; create liens on assets; make investments, loans or advances; make acquisitions or engage in mergers or consolidations; engage in certain transactions with our subsidiaries and affiliates; and make stock repurchases and dividend payments.

We have debt issuance costs related to our long-term debt that are being amortized using the straight-line method over the life of the debt, which approximates the effective interest method. Amortization expense for three and six months ended June 30, 2025 was $48 and $97, respectively. Amortization expense for the three and six months ended June 30, 2024 was $48 and $97, respectively. These costs are included in interest expense in our Consolidated Statements of Earnings.

**Note 11 - Derivative Financial Instruments**

Our earnings and cash flows are subject to fluctuations due to changes in foreign currency exchange rates and interest rates. We selectively use derivative financial instruments including foreign currency forward contracts as well as interest rate and cross-currency swaps to manage our exposure to these risks.

The use of derivative financial instruments exposes the Company to credit risk, which relates to the risk of nonperformance by a counterparty to the derivative contracts. We manage our credit risk by entering into derivative contracts with only highly rated financial institutions and by using netting agreements.

The effective portion of derivative gains and losses are recorded in accumulated other comprehensive income (loss) until the hedged transaction affects earnings upon settlement, at which time they are reclassified to cost of goods sold or net sales. If it is probable that an anticipated hedged transaction will not occur by the end of the originally specified time period, we reclassify the gains or losses related to that hedge from accumulated other comprehensive income (loss) to other income (expense), net.

We assess hedge effectiveness qualitatively by verifying that the critical terms of the hedging instrument and the forecasted transaction continue to match, and that there have been no adverse developments that have increased the risk that the counterparty will default. No recognition of ineffectiveness was recorded in our Condensed Consolidated Statements of Earnings for the three and six months ended June 30, 2025.

*Foreign Currency Hedges*

We use forward contracts to mitigate currency risk related to a portion of our forecasted foreign currency revenues and costs. The currency forward contracts are designed as cash flow hedges and are recorded in the Condensed Consolidated Balance Sheets at fair value.

We continue to monitor the Company's overall currency exposure and may elect to add cash flow hedges in the future. At June 30, 2025, we had a net unrealized gain of $2,311 in accumulated other comprehensive income (loss), $1,225 of which is expected to be reclassified to earnings within the next 12 months. The notional amount of foreign currency forward contracts outstanding was $64,999 at June 30, 2025.

*Interest Rate Swaps*

We use interest rate swaps to convert a portion of our Revolving Credit Facility's outstanding balance from a variable rate of interest to a fixed rate. As of June 30, 2025, we have agreements to fix interest rates on $50,000 of long-term debt until December 2026. The difference to be paid or received under the terms of the swap agreements will be recognized as an adjustment to interest expense when settled.

------

These swaps are treated as cash flow hedges and consequently, the changes in fair value are recorded in other comprehensive earnings (loss). The estimated net amount of the existing gains that are reported in accumulated other comprehensive income (loss) that are expected to be reclassified into earnings within the next twelve months is approximately $661.

*Cross-Currency Swap*

The Company has operations and investments in various international locations and is subject to risks associated with changing foreign exchange rates. In order to hedge the Krone-based purchase price for the acquisition of Ferroperm Piezoceramics, A.S. ("Ferroperm"), the Company entered into a cross-currency interest rate swap agreement on June 27, 2022 that synthetically swapped $25,000 of variable rate debt to Krone denominated variable rate debt. Upon completion of the Ferroperm acquisition on June 30, 2022, the transaction was designated as a net investment hedge for accounting purposes and will mature on June 30, 2027.

Accordingly, any gains or losses on this derivative instrument are included in the foreign currency translation component of other comprehensive earnings (loss) until the net investment is sold, diluted or liquidated. As of June 30, 2025, we had a net unrealized loss of $1,752 in accumulated other comprehensive income (loss). Interest payments received for the cross-currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense in the Condensed Consolidated Statements of Earnings. The assumptions used in measuring fair value of the cross-currency swap are considered level 2 inputs, which are based upon the Krone to U.S. Dollar exchange rate market.

The location and fair values of derivative instruments designated as hedging instruments in the Condensed Consolidated Balance Sheets as of June 30, 2025, are shown in the following table:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Interest rate swaps reported in Other current assets | $661 | $792 |
| Interest rate swaps reported in Other assets | 165 | 711 |
| Cross-currency swap reported in Other current assets | - | 324 |
| Cross-currency swap reported in Accrued expenses and other liabilities | (1092) | - |
| Foreign currency hedges reported in Other current assets | 2201 | - |
| Foreign currency hedges reported in Accrued expenses and other liabilities | - | (2992) |

---

The Company has elected to net its foreign currency derivative assets and liabilities in the balance sheet in accordance with ASC 210-20 (*Balance Sheet, Offsetting*). On a gross basis, there were foreign currency derivative assets of $3,907 and foreign currency derivative liabilities of $1,706 at June 30, 2025.

------

The effect of derivative instruments on the Condensed Consolidated Statements of Earnings is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Foreign Exchange Contracts:** |  |  |  |  |
| Amounts reclassified from AOCI to earnings: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net sales | $(232) | $70 | $(272) | $96 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | (315) | 384 | (946) | 1141 |
| Total net gain (loss) reclassified from AOCI to earnings | (547) | 454 | (1218) | 1237 |
| Total derivative gain (loss) on foreign exchange contracts recognized in earnings | $(547) | $454 | $(1218) | $1237 |
| **Interest Rate Swaps:** |  |  |  |  |
| Income recorded in Interest expense | $236 | $371 | $471 | $776 |
| **Cross-Currency Swap:** |  |  |  |  |
| Income recorded in Interest expense | $6 | $95 | $78 | $189 |
| Total net (loss) gain on derivatives | $(305) | $920 | $(669) | $2202 |

---

**NOTE 12 – Accumulated Other Comprehensive Income (Loss)**

Shareholders' equity includes certain items classified as accumulated other comprehensive income (loss) ("AOCI") in the Condensed Consolidated Balance Sheets, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Unrealized gains (losses) on hedges** relate to interest rate swaps to convert a portion of our Revolving Credit Facility's outstanding balance from a variable rate of interest into a fixed rate, foreign currency forward contracts used to hedge our exposure to changes in exchange rates affecting certain revenues and costs denominated in foreign currencies, as well as a cross-currency swap that synthetically converts our U.S. Dollar variable rate debt to Krone denominated variable rate debt. These hedges are designated as cash flow hedges, and we have deferred income statement recognition of gains and losses until the hedged transactions occur, at which time amounts are reclassified into earnings. Further information related to our derivative financial instruments is included in Note 11 – "Derivative Financial Instruments" and Note 15 – "Fair Value Measurements".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Unrealized gains (losses) on pension obligations** are deferred from income statement recognition until the gains or losses are realized. Amounts reclassified to income from AOCI are included in net periodic pension income (expense).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Cumulative translation adjustments** relate to our non-U.S. subsidiary companies that have designated a functional currency other than the U.S. Dollar. We are required to translate the subsidiary functional currency financial statements to dollars using a combination of historical, period-end, and average foreign exchange rates. This combination of rates creates the foreign currency translation adjustment component of other comprehensive earnings (loss).

Changes in exchange rates between the functional currency and the currency in which a transaction is denominated are foreign exchange transaction gains or losses. Transaction gains for the three and six months ended June 30, 2025 were $770 and $1,304, respectively. Transaction losses for the three and six months ended June 30, 2024 were $629 and $2,136, respectively. The impact of these changes are included in other income (expense) in the Condensed Consolidated Statements of Earnings.

------

The components of accumulated other comprehensive income (loss) for the three months ended June 30, 2025, are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | **(Gain) Loss** |  |
|  | **As of** | **Gain (Loss)** | **Reclassified** | **As of** |
|  | **March 31,** | **Recognized** | **from AOCI** | **June 30,** |
|  | **2025** | **in OCI** | **to Earnings** | **2025** |
| Changes in fair market value of derivatives: |  |  |  |  |
| Gross | $(585) | $3410 | $311 | $3136 |
| Income tax benefit (expense) | 128 | (801) | (73) | (746) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (457) | 2609 | 238 | 2390 |
| Changes in unrealized pension cost: |  |  |  |  |
| Gross | (395) |  | (128) | (523) |
| Income tax benefit (expense) | 300 |  | 5 | 305 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (95) |  | (123) | (218) |
| Cumulative translation adjustment: |  |  |  |  |
| Gross | 1824 | 8024 |  | 9848 |
| Income tax benefit (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | 1824 | 8024 |  | 9848 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accumulated other comprehensive (loss) income | $1272 | $10633 | $115 | $12020 |

---

The components of accumulated other comprehensive income (loss) for the three months ended June 30, 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | **(Gain) Loss** |  |
|  | **As of** | **Gain (Loss)** | **Reclassified** | **As of** |
|  | **March 31,** | **Recognized** | **from AOCI** | **June 30,** |
|  | **2024** | **in OCI** | **to Earnings** | **2024** |
| Changes in fair market value of derivatives: |  |  |  |  |
| Gross | $4201 | $(1350) | $(825) | $2026 |
| Income tax (expense) benefit | (967) | 310 | 190 | (467) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | 3234 | (1040) | (635) | 1559 |
| Changes in unrealized pension cost: |  |  |  |  |
| Gross | (1057) |  | 40 | (1017) |
| Income tax benefit (expense) | 437 |  | (5) | 432 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (620) |  | 35 | (585) |
| Cumulative translation adjustment: |  |  |  |  |
| Gross | 324 | (523) |  | (199) |
| Income tax benefit (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | 324 | (523) |  | (199) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accumulated other comprehensive income (loss) | $2938 | $(1563) | $(600) | $775 |

---

------

The components of accumulated other comprehensive income (loss) for the six months ended June 30, 2025 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | **(Gain) Loss** |  |
|  | **As of** | **Gain (Loss)** | **Reclassified** | **As of** |
|  | **December 31,** | **Recognized** | **from AOCI** | **June 30,** |
|  | **2024** | **in OCI** | **to Earnings** | **2025** |
| Changes in fair market value of derivatives: |  |  |  |  |
| Gross | $(1730) | $4118 | $748 | $3136 |
| Income tax benefit (expense) | 397 | (968) | (175) | (746) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (1333) | 3150 | 573 | 2390 |
| Changes in unrealized pension cost: |  |  |  |  |
| Gross | (409) |  | (114) | (523) |
| Income tax benefit (expense) | 300 |  | 5 | 305 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (109) |  | (109) | (218) |
| Cumulative translation adjustment: |  |  |  |  |
| Gross | (2824) | 12672 |  | 9848 |
| Income tax benefit (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (2824) | 12672 |  | 9848 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accumulated other comprehensive (loss) income | $(4266) | $15822 | $464 | $12020 |

---

The components of accumulated other comprehensive income (loss) for the six months ended June 30, 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | **(Gain) Loss** |  |
|  | **As of** | **Gain (Loss)** | **Reclassified** | **As of** |
|  | **December 31,** | **Recognized** | **from AOCI** | **June 30,** |
|  | **2023** | **in OCI** | **to Earnings** | **2024** |
| Changes in fair market value of derivatives: |  |  |  |  |
| Gross | $3252 | $788 | $(2014) | $2026 |
| Income tax benefit (expense) | (749) | (181) | 463 | (467) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | 2503 | 607 | (1551) | 1559 |
| Changes in unrealized pension cost: |  |  |  |  |
| Gross | (1126) |  | 109 | (1017) |
| Income tax benefit (expense) | 442 |  | (10) | 432 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | (684) |  | 99 | (585) |
| Cumulative translation adjustment: |  |  |  |  |
| Gross | 2445 | (2644) |  | (199) |
| Income tax benefit (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | 2445 | (2644) |  | (199) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accumulated other comprehensive (loss) income | $4264 | $(2037) | $(1452) | $775 |

---

------

**NOTE 13 – Shareholders' Equity**

Share count and par value data related to shareholders' equity are as follows:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Preferred Stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Par value per share | No par value | No par value |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares authorized | 25000000 | 25000000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares outstanding |  |  |
| Common Stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Par value per share | No par value | No par value |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares authorized | 75000000 | 75000000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares issued | 57621847 | 57543964 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares outstanding | 29548737 | 30026045 |
| Treasury stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares held | 28073110 | 27517919 |

---

On February 2, 2024, our Board of Directors approved a new share repurchase program that authorizes the Company to repurchase up to $100,000 of its common stock. The repurchase program has no set expiration date and supersedes and replaces the repurchase program approved by the Board of Directors in February 2023. The purchases may be made from time to time in the open market (including, without limitation, through the use of Rule 10b5-1 plans), depending on a number of factors, including our evaluation of general market and economic conditions, our financial condition and the trading price of our common stock. The repurchase program may be extended, modified, suspended or discontinued at any time.

During the three and six months ended June 30, 2025, 411,650 and 555,191 shares of common stock were repurchased for $16,694 and $23,345, respectively, across both share repurchase programs. During the three and six months ended June 30, 2024, 228,000 and 499,939 shares of common stock were repurchased for $11,129 and $23,207, respectively. As of June 30, 2025, approximately $38,078 remains available for future purchases.

We are subject to a 1% excise tax on stock repurchases under the United States Inflation Reduction Act of 2022 which we include in the cost of stock repurchases as a reduction of shareholders' equity. As of June 30, 2025 and December 31, 2024, we had $127 and $741, respectively, recorded in Accrued expenses and other liabilities in the Consolidated Balance Sheet.

A roll-forward of common shares outstanding is as follows:

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Balance at the beginning of the year | 30026045 | 30824248 |
| Repurchases | (555191) | (499939) |
| Restricted share issuances | 77883 | 97481 |
| Balance at the end of the period | 29548737 | 30421790 |

---

Certain potentially dilutive restricted stock units are excluded from diluted earnings per share because they are anti-dilutive. The number of outstanding awards that were anti-dilutive for the three and six months ended June 30, 2025 was 3,652 and 908. The number of outstanding awards that were anti-dilutive for the three and six months ended June 30, 2024 was 2,391 and 6,461.

**NOTE 14 - Stock-Based Compensation**

At June 30, 2025, we had five active stock-based compensation plans: the Non-Employee Directors' Stock Retirement Plan ("Directors' Plan"), the 2004 Omnibus Long-Term Incentive Plan ("2004 Plan"), the 2009 Omnibus Equity and Performance Incentive Plan ("2009 Plan"), the 2014 Performance and Incentive Compensation Plan ("2014 Plan"), and the 2018 Equity and Incentive Compensation Plan ("2018 Plan"). Future grants can only be made under the 2018 Plan.

------

The 2018 Plan allows for grants of stock options, stock appreciation rights, restricted stock, restricted stock units ("RSUs"), performance shares, performance units, and other stock awards subject to the terms of the 2018 Plan.

The following table summarizes the compensation expense included in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings related to stock-based compensation plans:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Service-based RSUs | $643 | $981 | $1591 | $1875 |
| Performance and Market-based RSUs | (143) | 215 | 341 | 370 |
| Cash-settled RSUs | 116 | 136 | 331 | 299 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $616 | $1332 | $2263 | $2544 |
| Income tax benefit | 145 | 306 | 532 | 585 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net expense | $471 | $1026 | $1731 | $1959 |

---

The following table summarizes the unrecognized compensation expense related to unvested RSUs by type and the weighted-average period in which the expense is to be recognized:

---

| | | |
|:---|:---|:---|
|  | **Unrecognized** |  |
|  | **Compensation** | **Weighted-** |
|  | **Expense at** | **Average** |
|  | **June 30, 2025** | **Period (years)** |
| Service-based RSUs | $3558 | 1.39 |
| Performance and Market-based RSUs | 3890 | 2.15 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $7448 | 1.79 |

---

We recognize expense on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards.

The following table summarizes the status of these plans as of June 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **2018 Plan** | **2014 Plan** | **2009 Plan** | **2004 Plan** | **Directors'<br>Plan** |
| Awards originally available | 2500000 | 1500000 | 3400000 | 6500000 | N/A |
| Maximum potential awards outstanding | 639753 | 39400 | 34100 | 14545 | 4722 |
| RSUs and cash-settled awards vested and released | 771459 |  |  |  |  |
| Awards available for grant | 1088788 |  |  |  |  |

---

**Service-Based Restricted Stock Units** 

The following table summarizes the service-based RSU activity for the six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
|  | **Units** | **Weighted<br>Average <br>Grant Date <br>Fair Value** |
| Outstanding at December 31, 2024 | 322847 | $34.06 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 61908 | 46.24 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested and released | (54944) | 40.40 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (20691) | 44.78 |
| Outstanding at June 30, 2025 | 309120 | $34.70 |
| Releasable at June 30, 2025 | 158467 | $23.78 |

---

------

**Performance and Market-Based Restricted Stock Units**

The following table summarizes the performance and market-based RSU activity for the six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
|  | **Units** | **Weighted<br>Average <br>Grant Date <br>Fair Value** |
| Outstanding at December 31, 2024 | 222344 | $40.15 |
| Granted | 75010 | 46.46 |
| Attained by performance | 39581 | 37.93 |
| Released | (79162) | 37.93 |
| Forfeited | (71864) | 35.95 |
| Outstanding at June 30, 2025 | 185909 | $44.64 |
| Releasable at June 30, 2025 |  | $— |

---

**Cash-Settled Restricted Stock Units**

Cash-Settled RSUs entitle the holder to receive the cash equivalent of one share of common stock for each unit when the unit vests. These RSUs are issued to key employees residing in foreign locations as direct compensation. Generally, these RSUs vest over a three-year period. Cash-Settled RSUs are classified as liabilities and are remeasured at each reporting date until settled. At June 30, 2025 and December 31, 2024, we had 15,028 and 44,127 cash-settled RSUs outstanding, respectively. At June 30, 2025 and December 31, 2024 liabilities of $390 and $608, respectively, were included in Accrued expenses and other liabilities on our Condensed Consolidated Balance Sheets.

**NOTE 15 - Fair Value Measurements**

The table below summarizes our financial assets and liabilities that were measured at fair value on a recurring basis as of June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Asset (Liability) Carrying<br>Value at<br>June 30,<br>2025** | **Quoted Prices<br>in Active<br>Markets for<br>Identical<br>(Level 1)** | **Significant<br>Other<br>Observable<br>Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** |
| Interest rate swaps | $826 | $— | $826 | $— |
| Foreign currency hedges | $2201 | $— | $2201 | $— |
| Cross-currency swap | $(1092) | $— | $(1092) | $— |
| Qualified replacement plan assets | $10172 | $10172 | $— | $— |
| Contingent consideration | $(5505) | $— | $— | $(5505) |

---

The table below summarizes the financial assets and liabilities that were measured at fair value on a recurring basis as of December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Asset (Liability) Carrying<br>Value at<br>December 31,<br>2024** | **Quoted Prices<br>in Active<br>Markets for<br>Identical<br>(Level 1)** | **Significant<br>Other<br>Observable<br>Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** |
| Interest rate swaps | $1503 | $— | $1503 | $— |
| Foreign currency hedges | $(2992) | $— | $(2992) | $— |
| Cross-currency swap | $324 | $— | $324 | $— |
| Qualified replacement plan assets | $11380 | $11380 | $— | $— |
| Contingent consideration | $(7028) | $— | $— | $(7028) |

---

------

We use interest rate swaps to convert a portion of our Revolving Credit Facility's outstanding balance from a variable rate of interest into a fixed rate and foreign currency forward contracts to hedge the effect of foreign currency changes on certain revenues and costs denominated in foreign currencies. The Company entered into a cross-currency swap agreement in order to manage its exposure to changes in interest rates related to foreign debt. These derivative financial instruments are measured at fair value on a recurring basis. The fair value of our interest rate swaps and foreign currency hedges were measured using standard valuation models using market-based observable inputs over the contractual terms, including forward yield curves, among others. There is a readily determinable market for these derivative instruments, but that market is not active and therefore they are classified within Level 2 of the fair value hierarchy.

The fair value of the contingent consideration requires significant judgment. The Company's fair value estimates used in the contingent consideration valuation are considered Level 3 fair value measurements. The fair value estimates were based on assumptions management believes to be reasonable, but that are inherently uncertain, including estimates of future revenues and timing of events and activities that are expected to take place.

A roll-forward of the contingent consideration is as follows:

---

| | |
|:---|:---|
|  | **Contingent<br>Consideration** |
| Balance at December 31, 2024 | $7028 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value | (1523) |
| Balance at June 30, 2025 | $5505 |

---

As of June 30, 2025, $623 in contingent consideration was recorded in Accrued expenses and other liabilities and $4,882 in Other long-term obligations on our Condensed Consolidated Balance Sheets.

Our long-term debt consists of the Revolving Credit Facility, which is recorded at its carrying value. There is a readily determinable market for our long-term debt and it is classified within Level 2 of the fair value hierarchy as the market is not deemed to be active. The fair value of long-term debt approximates its carrying value and was determined by valuing a similar hypothetical coupon bond and attributing that value to our long-term debt under the Revolving Credit Facility.

The qualified replacement plan assets consist of investment funds maintained for future contributions to the Company's U.S. 401(k) program. The investments are Level 1 marketable securities and are recorded in Other Assets on our Condensed Consolidated Balance Sheets.

**NOTE 16 - Income Taxes**

The effective income tax rates for the three and six months ended June 30, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Effective tax rate | 19.4% | 17.2% | 18.4% | 17.8% |

---

Our effective income tax rate was 19.4% and 17.2% in the second quarter of 2025 and 2024, respectively. The increase in the effective income tax rate is primarily attributable to a change in mix of earnings taxed at higher rates. The second quarter 2025 effective income tax rate was lower than the U.S. statutory federal tax rate primarily due to foreign earnings that are taxed at lower rates. The second quarter 2024 effective income tax rate was lower than the U.S. statutory federal tax rate primarily due to foreign earnings that are taxed at lower rates.

------

Our effective income tax rate was 18.4% and 17.8% in the six months ended June 30, 2025 and 2024, respectively. The increase in the effective income tax rate is primarily attributable to a mix of earnings taxed at higher rates. The effective income tax rate in the first six months of 2025 was lower than the U.S. statutory federal income tax rate primarily due to foreign earnings that are taxed at lower rates and tax benefits recorded upon the vesting of restricted stock units. The effective income tax rate in the first six months of 2024 was lower than the U.S. statutory federal income tax rate primarily due to foreign earnings that are taxed at lower rates and tax benefits recorded upon the vesting of restricted stock units.

The One Big Beautiful Bill Act (the "OBBBA") was signed into law on July 4, 2025. The OBBBA contains significant tax law changes with various effective dates after its enactment date. The Company is currently evaluating the impacts that the tax law changes will have on its financial position and results of operation. An estimate cannot be made at this time.

**NOTE 17 - Segment Information**

The Company designs, manufactures, and sells a broad line of sensors, connectivity components, and actuators across multiple end markets in North America, Asia, and Europe. Our Chief Operating Decision Maker ("CODM"), who is our Chair, President and Chief Executive Officer, analyzes the results of our business through one reportable segment. Our CODM evaluates the operating results and performance through Net earnings, which are reported on the Consolidated Statements of Earnings. These financial metrics are used to view operating trends, perform analytical comparisons and benchmark performance between periods and to monitor budget-to-actual variances on a monthly basis. To manage operations and make decisions regarding resources, our CODM is regularly provided and reviews expense information at a consolidated level for our Cost of goods sold, Selling, general, and administrative expenses and Research and Development expenses, which are reported on the Consolidated Statements of Earnings. As part of our strategic planning and annual operating plan, a focus is on sales growth, diversification, and profitability. The measure of segment assets is reported on the Consolidated Balance Sheet as Total Assets, but the CODM does not use discrete balance sheet information in assessing performance and allocating resources.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A")**

(in thousands, except percentages and per share amounts)

The following discussion should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and notes included under Item 1, as well as our Consolidated Financial Statements and notes and related Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2024.

**Overview**

CTS is a global manufacturer of sensors, connectivity components, and actuators. CTS was established in 1896 as a provider of high-quality telephone products and was incorporated as an Indiana corporation in February 1929. Our principal executive offices are located in Lisle, Illinois.

We design, manufacture, and sell a broad line of sensors, connectivity components, and actuators primarily to original equipment manufacturers ("OEMs"), tier one suppliers for the aerospace and defense, industrial, medical, and transportation markets, and the U.S. Government. Our vision is to be a leading provider of sensing and motion devices as well as connectivity components, enabling an intelligent and seamless world. These devices are categorized by their ability to Sense, Connect or Move. Sense products provide vital inputs to electronic systems. Connect products allow systems to function in synchronization with other systems. Move products ensure required movements are effectively and accurately executed. We are committed to achieving our vision by continuing to invest in the development of products, technologies, and talent within these categories.

We operate manufacturing facilities in North America, Asia, and Europe. Sales and marketing are accomplished through our sales engineers. We also utilize independent manufacturers' representatives and distributors to extend our sales capability.

There is an increasing proliferation of sensing and motion applications within various markets we serve. In addition, the increasing connectivity of various devices to the internet results in greater demand for communication bandwidth and data storage, increasing the need for our connectivity products. Our success is dependent on the ability to execute our strategy to support these trends. We are subject to a number of challenges including, without limitation, periodic market softness, competition from other suppliers, changes in technology, changes in the economy generally, including inflationary and/or recessionary conditions and increased tariffs, as well as the ability to add new customers, launch new products or penetrate new markets. Many of these, and other risks and uncertainties relating to the Company and our business, are discussed in further detail in Item 1A. of our Annual Report on Form 10-K and other filings made with the SEC.

------

**Results of Operations: Second Quarter 2025 versus Second Quarter 2024**

The following table highlights changes in significant components of the Unaudited Condensed Consolidated Statements of Earnings for the quarters ended June 30, 2025 and June 30, 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |  |  |  |
|  | **June 30, 2025** | **June 30, 2024** | **Percent<br>Change** | **Percentage of Net Sales –<br>2025** | **Percentage of Net Sales –<br>2024** |
| Net sales | $135309 | $130162 | 4.0% | 100.0% | 100.0% |
| Cost of goods sold | 82878 | 83790 | (1.1) | 61.3 | 64.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin | 52431 | 46372 | 13.1 | 38.7 | 35.6 |
| Selling, general and administrative expenses | 23077 | 21332 | 8.2 | 17.1 | 16.4 |
| Research and development expenses | 6326 | 6086 | 3.9 | 4.7 | 4.7 |
| Restructuring charges | 297 | 1190 | (75.0) | 0.2 | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 29700 | 28608 | 3.8 | 21.9 | 22.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating earnings | 22731 | 17764 | 28.0 | 16.8 | 13.6 |
| Total other income (expense), net | 251 | 5 | 4920.0 | 0.2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before income taxes | 22982 | 17769 | 29.3 | 17.0 | 13.7 |
| Income tax expense | 4455 | 3062 | 45.5 | 3.3 | 2.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net earnings | $18527 | $14707 | 26.0% | 13.7% | 11.3% |
| Earnings per share: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted net earnings per share | $0.62 | $0.48 |  |  |  |

---

Net sales were $135,309 in the second quarter of 2025, an increase of $5,147 or 4.0% from the second quarter of 2024. Net sales to the diversified end markets increased $8,694 or 13.2%. SyQwest added $4,468 in sales during the quarter. We achieved growth in the medical end market and saw continued recovery in the industrial end market. Net sales to the transportation end market decreased $3,547 or 5.5%, primarily driven by lower volumes of our commercial vehicle related products and lower sales to customers in China. Net sales increased $952 year-over-year related to changes in foreign exchange rates, primarily due to the U.S. Dollar depreciating compared to the Euro.

Gross margin was $52,431 in the second quarter of 2025, an increase of $6,059 or 13.1% from the second quarter of 2024. Our gross margin percentage increased from 35.6% for the second quarter of 2024 to 38.7% for the second quarter of 2025 due to improved mix of sales by end market and operational improvements. Additionally, changes in foreign exchange rates had a net benefit on our gross margin of approximately $959 primarily due to rate changes between the U.S. Dollar and the Mexican Peso.

Selling, general and administrative ("SG&A") expenses were $23,077 or 17.1% of net sales in the second quarter of 2025 versus $21,332 or 16.4% of net sales in the second quarter of 2024. The increase in SG&A expenses was primarily driven by higher depreciation and amortization expense in the second quarter of 2025 from the SyQwest acquisition.

Research and development ("R&D") expenses were $6,326 or 4.7% of net sales in the second quarter of 2025 compared to $6,086 or 4.7% of net sales in the comparable quarter of 2024. Our R&D expenses are in line with our commitment to continue investing in research and product development to drive organic growth.

Restructuring charges were $297 or 0.2% of net sales in the second quarter of 2025 compared to $1,190 or 0.9% of net sales in the second quarter of 2024. The restructuring charges in the quarter ended June 30, 2025 were primarily related to headcount reductions in response to softening demand in the transportation end market. See Note 7 "Costs Associated with Exit and Restructuring Activities" in the Notes to the Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for further information.

------

Other income and expense items are summarized in the following table:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Interest expense | $(1121) | $(833) |
| Interest income | 622 | 1441 |
| Other income (expense), net | 750 | (603) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other expense, net | $251 | $5 |

---

Interest income decreased due to lower investments of available cash as a result of the SyQwest acquisition in the third quarter of 2024. Interest expense increased due to higher borrowings to fund the SyQwest acquisition.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Effective tax rate | 19.4% | 17.2% |

---

Our effective income tax rate was 19.4% and 17.2% in the second quarters of 2025 and 2024, respectively. The increase in the effective income tax rate is primarily attributable to a mix of earnings taxed at higher rates.

**Results of Operations: Six Months ended June 30, 2025 versus Six Months Ended June 30, 2024**

The following table highlights changes in significant components of the Unaudited Condensed Consolidated Statements of Earnings for the six months ended June 30, 2025, and June 30, 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |  |  |  |
|  | **June 30, 2025** | **June 30, 2024** | **Percent<br>Change** | **Percentage of Net Sales –<br>2025** | **Percentage of Net Sales –<br>2024** |
| Net sales | $261078 | $255912 | 2.0% | 100.0% | 100.0% |
| Cost of goods sold | 162099 | 164450 | (1.4) | 62.1 | 64.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin | 98979 | 91462 | 8.2 | 37.9 | 35.7 |
| Selling, general and administrative expenses | 46700 | 43591 | 7.1 | 17.9 | 17.0 |
| Research and development expenses | 12515 | 12687 | (1.4) | 4.8 | 5.0 |
| Restructuring charges | 749 | 2884 | (74.0) | 0.3 | 1.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 59964 | 59162 | 1.4 | 23.0 | 23.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating earnings | 39015 | 32300 | 20.8 | 14.9 | 12.6 |
| Total other income (expense), net | 86 | (874) | (109.8) |  | (0.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before income taxes | 39101 | 31426 | 24.4 | 15.0 | 12.3 |
| Income tax expense | 7210 | 5600 | 28.8 | 2.8 | 2.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net earnings | $31891 | $25826 | 23.5% | 12.2% | 10.1% |
| Earnings per share: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted net earnings per share | $1.06 | $0.84 |  |  |  |

---

Net sales were $261,078 in the six months ended June 30, 2025, an increase of $5,166 or 2.0% from the six months ended June 30, 2024. Net sales to the diversified end markets increased $16,741 or 13.4%. SyQwest added $7,878 in sales during the first half of the year. We have good growth momentum in the medical end market and the industrial end market continues to recover. Net sales to the transportation market decreased $11,575 or 8.9%, primarily driven by lower volumes of our commercial vehicle related products and lower sales to customers in China.

Gross margin was $98,979 for the six months ended June 30, 2025, an increase of $7,517 or 8.2% from the six months ended June 30, 2024. Our gross margin percentage was 37.9% for the first six months of 2025, an increase from 35.7% in the first six months of 2024 due to improved mix of sales by end market and operational improvements. Additionally, changes in foreign exchange rates had a net benefit on our gross margin of approximately $2,026 primarily due to rate changes between the U.S. Dollar and the Mexican Peso.

------

SG&A expenses were $46,700 or 17.9% of net sales for the six months ended June 30, 2025 versus $43,591 or 17.0% of net sales for the six months ended June 30, 2024. The increase in SG&A expenses was primarily driven by higher depreciation and amortization expense in 2025 from the SyQwest acquisition.

R&D expenses were $12,515 or 4.8% of net sales for the six months ended June 30, 2025 compared to $12,687 or 5.0% of net sales for the six months ended June 30, 2024.

Restructuring charges were $749 or 0.3% of net sales for the six months ended June 30, 2025 compared to $2,884 or 1.1% of net sales for the six months ended June 30, 2024. The restructuring charges in the six months ended June 30, 2025 were primarily related to headcount reductions in response to softening demand in the transportation end market. See Note 7 "Costs Associated with Exit and Restructuring Activities" in the Notes to the Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for further information.

Other income and expense items are summarized in the following table:

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Interest expense | $(2289) | $(1635) |
| Interest income | 1068 | 2827 |
| Other income (expense), net | 1307 | (2066) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other (expense) income, net | $86 | $(874) |

---

Interest income decreased due to lower investments of available cash into short-term, cash equivalent, high-yield deposit accounts as a result of the SyQwest acquisition in the third quarter of 2024. Interest expense increased due to higher borrowings to fund the SyQwest acquisition.

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Effective tax rate | 18.4% | 17.8% |

---

Our effective income tax rate was 18.4% and 17.8% for the six months ended June 30, 2025 and 2024, respectively. The increase in the effective income tax rate is primarily attributable to a mix of earnings taxed at higher rates.

**Liquidity and Capital Resources**

We have historically funded our capital and operating needs primarily through cash flows from operating activities, supported by available credit under our Revolving Credit Facility (as defined below). We believe that cash flows from operating activities and available borrowings under our Revolving Credit Facility will be adequate to fund our working capital needs, capital expenditures, investments, and debt service requirements for at least the next twelve months and for the foreseeable future thereafter. However, we may choose to pursue additional equity and debt financing to provide additional liquidity or to fund acquisitions.

Cash and cash equivalents were $99,440 at June 30, 2025, and $94,334 at December 31, 2024, of which $98,785 and $92,944, respectively, were held outside the United States. Total long-term debt was $88,000 as of June 30, 2025 and $92,300 as of December 31, 2024.

***Cash Flow Overview***

*Cash Flows from Operating Activities*

Net cash provided by operating activities was $43,870 during the six months ended June 30, 2025. Components of net cash provided by operating activities included net earnings of $31,891, depreciation and amortization expense of $17,045, other net non-cash items of $838, and a net cash outflow from changes in assets and liabilities of $5,904.

------

Net cash provided by operating activities was $37,940 during the six months ended June 30, 2024. Components of net cash provided by operating activities included net earnings of $25,826, depreciation and amortization expense of $14,651, other net non-cash items of $629, and a net cash outflow from changes in assets and liabilities of $3,166.

*Cash Flows from Investing Activities*

Net cash used in investing activities for the six months ended June 30, 2025 was $7,745 for payments on capital expenditures.

Net cash used in investing activities for the six months ended June 30, 2024 was $8,672 for payments on capital expenditures.

*Cash Flows from Financing Activities*

Net cash used in financing activities for the six months ended June 30, 2025 was $32,351. The net cash outflow was the result of treasury stock purchases of $22,995, net cash payments of long-term debt of $4,300, taxes paid on behalf of equity award participants of $2,655, and dividends paid of $2,401.

Net cash used in financing activities for the six months ended June 30, 2024 was $32,059. The net cash outflow was the result of treasury stock purchases of $22,892, net cash used in the paydown of long-term debt of $2,500, taxes paid on behalf of equity award participants of $3,131, dividends paid of $2,460, and payments of contingent consideration of $1,076.

***Capital Resources***

*Revolving Credit Facility*

Long-term debt is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Total credit facility | $400000 | $400000 |
| Balance outstanding | 88000 | 92300 |
| Standby letters of credit | 1640 | 1640 |
| Amount available, subject to covenant restrictions | $310360 | $306060 |

---

On December 15, 2021, we entered into a second amended and restated five-year credit agreement with a group of banks (the "Revolving Credit Facility") to (i) increase the total credit facility availability to $400,000, which may be increased by $200,000 at the request of the Company, subject to the administrative agent's approval, (ii) extend the maturity of the Revolving Credit Facility from February 12, 2024 to December 15, 2026, (iii) replace LIBOR with SOFR as the primary reference rate used to calculate interest on the loans under the Revolving Credit Facility, (iv) increase available sub limits for letters of credit, and swingline loans as well as providing for additional alternative currency borrowing capabilities, and (v) modify the financial and non-financial covenants to provide the Company additional flexibility. This new unsecured credit facility replaced the prior $300,000 unsecured credit facility, which would have expired February 12, 2024.

Borrowings in U.S. Dollars under the Revolving Credit Facility bear interest, at a per annum rate equal to the applicable Term SOFR rate (but not less than 0.0%), plus the Term SOFR adjustment, and plus an applicable margin, which ranges from 1.00% to 1.75%, based on our net leverage ratio. Similarly, borrowings of alternative currencies under the Revolving Credit Facility bear interest equal to a defined risk-free reference rate, plus the applicable risk-free rate adjustment and plus an applicable margin, which ranges from 1.00% to 1.75%, based on our net leverage ratio. We use interest rate swaps to convert a portion of our revolving credit facility's outstanding balance from a variable rate of interest to a fixed rate. The contractual rate of these arrangements ranges from 1.49% to 2.45%.

The Revolving Credit Facility includes a swing-line sublimit of $20,000 and a letter of credit sublimit of $20,000. We also pay a quarterly commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee ranges from 0.175% to 0.25% based on our net leverage ratio. We were in compliance with all debt covenants at June 30, 2025.

------

**Critical Accounting Policies and Estimates**

The Company's Condensed Consolidated Financial Statements are prepared in accordance with U.S. GAAP. In connection with the preparation of the Condensed Consolidated Financial Statements, the Company uses estimates and makes judgments and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. The assumptions, estimates, and judgments are based on historical experience, current trends, and other factors the Company believes are relevant at the time it prepares the Condensed Consolidated Financial Statements.

The critical accounting policies and estimates are consistent with those discussed in Note 1, Summary of Significant Accounting Policies, to the Consolidated Financial Statements and the MD&A section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024. During and as of the three and six months ended June 30, 2025, there were no significant changes in the application of critical accounting policies or estimates.

**Significant Customers**

Our net sales to customers representing at least 10% of total net sales is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Toyota Motor Corporation | 12.0% | 11.9% | 12.0% | 12.6% |
| Cummins Inc. | 9.5% | 13.1% | 9.9% | 13.4% |

---

No other customer accounted for 10% or more of total net sales during these periods. We continue to focus on broadening our customer base to diversify our non-transportation end market exposure.

------

**Forward**-**Looking Statements**

Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, "forward-looking statements" as defined by the "safe harbor" provisions in the Private Securities Litigation Reform Act of 1995. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included or incorporated in this document, including statements regarding our strategy, financial position, guidance, funding for continued operations, cash reserves, liquidity, projected costs, plans, projects, awards and contracts, and objectives of management, among others, are forward-looking statements. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "continued," "project," "plan," "goals," "opportunity," "appeal," "estimate," "potential," "predict," "demonstrates," "may," "will," "might," "could," "intend," "shall," "possible," "would," "approximately," "likely," "outlook," "schedule," "on track," "poised," "pipeline," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of future performance, conditions or results. Forward-looking statements are based on management's expectations, certain assumptions, and currently available information. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on various assumptions as to future events, the occurrence of which necessarily are subject to uncertainties. These forward-looking statements are made subject to certain risks, uncertainties, and other factors, which could cause CTS' actual results, performance, or achievements to differ materially from those presented in the forward-looking statements. Examples of factors that may affect future operating results and financial condition include, but are not limited to: supply chain disruptions; changes in the economy generally, including inflationary and/or recessionary conditions and increased tariffs, and in respect to the business in which CTS operates; unanticipated issues in integrating acquisitions including, without limitation the integration of SyQwest; the funding of contracts by the US Government; the results of actions to reposition CTS' business; rapid technological change; general market conditions in the transportation, as well as conditions in the industrial, aerospace and defense, and medical markets; reliance on key customers; unanticipated public health crises, natural disasters or other events; environmental compliance and remediation expenses; the ability to protect CTS' intellectual property; pricing pressures and demand for CTS' products; risks associated with CTS' international operations, including trade and tariff barriers, exchange rates and political and geopolitical risks (including, without limitation, the impact of tariffs on China, Canada and Mexico, and other nations, the potential impact of U.S./China relations and the impact of the conflicts in Ukraine, and the Middle East may have on our business, results of operations and financial condition); the amount and timing of any share repurchases; and the effect of any cybersecurity incidents on our business. Many of these, and other risks and uncertainties, are discussed in further detail in Item 1A. of CTS' most recent Annual Report on Form 10-K and other filings made with the SEC. CTS undertakes no obligation to publicly update CTS' forward-looking statements to reflect new information or events or circumstances that arise after the date hereof, including market or industry changes.

**Item 3. <u>Quantitative and Qualita</u><u>tive Disclosures About Market Risk</u>**

See Item 7A, Quantitative and Qualitative Disclosures about Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2024. During the six months ended June 30, 2025, there have been no material changes in our exposure to market risk.

------

**Item 4. <u>Control</u><u>s and Procedures</u>**

*Evaluation of Disclosure Controls and Procedures*

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within CTS have been detected.

*Changes in Internal Control Over Financial Reporting*

There were no changes in our internal control over financial reporting for the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**Item 1. <u>Legal</u> <u>Proceedings</u>**

From time to time, we are involved in litigation with respect to matters arising from the ordinary conduct of our business, and currently certain claims are pending against us. In the opinion of management, we believe we have established adequate accruals pursuant to U.S. generally accepted accounting principles for our expected future liability with respect to pending lawsuits, claims and proceedings, where the nature and extent of any such liability can be reasonably estimated based on presently available information. However, there can be no assurance that the final resolution of any existing or future lawsuits, claims or proceedings will not have a material adverse effect on our business, results of operations, financial condition, or cash flows.

See Note 9 "Commitments and Contingencies" in the Notes to the Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

**Item 1A. <u>Ri</u><u>sk Factors</u>**

Uncertainty over global tariffs and trade policies, or the financial impact of tariffs and trade policies, may negatively affect our results.

In the first half of 2025, there were significant changes to tariffs by the U.S. and other countries. The tariff modifications are at various rates, with exemptions applicable to some categories of imports and exports. While we are attempting to mitigate tariff-related impacts with a focus on agility in adapting to cost and price adjustments, there can be no assurance our mitigation efforts will be successful. The Company's management continues to monitor and evaluate the ongoing situation, with plans formulated to respond to a varied range of potential market scenarios. Additional tariffs or future changes to the U.S.'s or other countries' trade relations could further impact our business and negatively affect our results of operations.

There have been no other changes to our risk factors from those contained in our Annual Report on Form 10-K for the year ended December 31, 2024.

------

**Item 2. <u>Unregistered Sales of Equi</u><u>ty Securities and Use of Proceeds</u>** 

On February 2, 2024, the Board of Directors approved a share repurchase program that authorizes the Company to repurchase up to $100 million of its common stock. The share repurchase program has no set expiration date and supersedes and replaces the repurchase program approved by the Board of Directors in February 2023.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | **Total Number** | **Maximum Dollar** |
|  |  |  | **of Shares** | **Value of Shares** |
|  |  |  | **Purchased as** | **That May Yet Be** |
|  | **Total Number** |  | **Part of Publicly** | **Purchased Under** |
|  | **of Shares** | **Average Price** | **Announced** | **Publicly Announced** |
| **Period** | **Purchased** | **Paid per Share** | **Programs** | **Plans or Programs** |
| April 1, 2025 - April 30, 2025 | 153000 | $38.48 | 153000 | $48884512 |
| May 1 2025 - May 31, 2025 | 138650 | $41.11 | 138650 | $43184717 |
| June 1 , 2025 - June 30, 2025 | 120000 | $42.56 | 120000 | $38077599 |
| **Total** | **411650** |  | **411650** |  |

---

**Item 5. <u>Other Information</u>** 

From time to time, our directors and officers may purchase or sell shares of our common stock in the market, including pursuant to plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended ("Rule 10b5-1 Plans").

During the quarter ended June 30, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408 of Regulation S-K).

------

**Item 6. <u>Exhibits</u>**

---

| | |
|:---|:---|
| (31)(a) | [<u>Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](cts-ex31_a.htm) |
| (31)(b) | [<u>Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](cts-ex31_b.htm) |
| (32)(a) | [<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](cts-ex32_a.htm) |
| (32)(b) | [<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](cts-ex32_b.htm) |
| 101.1 | The following information from CTS Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 formatted in Inline XBRL: (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Earnings; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Cash Flows; (v) Condensed Consolidated Statements of Shareholders' Equity; (vi) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| 104 | The cover page from this Current Report on Form 10-Q formatted as inline XBRL |

---

------

**<u>SIGNAT</u><u>URES</u>**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| |
|:---|
| **CTS Corporation** |
| */s/ Ashish Agrawal* |
| Ashish Agrawal |
| Vice President and Chief Financial Officer<br>(Principal Financial Officer & Principal Accounting Officer) |
| Dated: July 24, 2025 |

---

------

## Ex-31.(A)

**EXHIBIT (31)(a)**

**<u>CERTIFICATION</u>**

I, Kieran O'Sullivan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CTS Corporation:

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: July 24, 2025 | */s/ Kieran O'Sullivan* |
|  | Kieran O'Sullivan |
|  | Chairman, President and Chief Executive Officer |

---

------

## Ex-31.(B)

**EXHIBIT (31)(b)**

**<u>CERTIFICATION</u>**

I, Ashish Agrawal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CTS Corporation:

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: July 24, 2025 | */s/Ashish Agrawal* |
|  | Ashish Agrawal |
|  | Vice President and Chief Financial Officer |

---

------

## Ex-32.(A)

**EXHIBIT (32)(a)**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of CTS Corporation (the Company) on Form 10-Q for the quarter ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: July 24, 2025 | */s/ Kieran O'Sullivan* |
|  | Kieran O'Sullivan |
|  | Chairman, President and Chief Executive Officer |

---

A signed original of this written statement required by Section 906 has been provided to CTS Corporation and will be retained by CTS Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Ex-32.(B)

**EXHIBIT (32)(b)**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of CTS Corporation (the Company) on Form 10-Q for the quarter ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: July 24, 2025 | */s/Ashish Agrawal* |
|  | Ashish Agrawal |
|  | Vice President and Chief Financial Officer |

---

A signed original of this written statement required by Section 906 has been provided to CTS Corporation and will be retained by CTS Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

------